Kamada Ltd Stock Price, News & Analysis

Kamada Ltd. (NASDAQ: KMDA) reported Q1 2021 revenues of $24.9 million, reflecting a 25% decline from Q1 2020. The net income was $2.7 million or $0.06 per share, down from $5.2 million or $0.12 per share last year. Adjusted EBITDA was $3.7 million, compared to $6.3 million in Q1 2020. Kamada plans to transfer the GLASSIA manufacturing license to Takeda by year-end, receiving $2 million. The company will also downsizes its workforce to cut costs by 10% annually. The Phase 3 InnovAATe trial for inhaled AAT continues, and Kamada remains focused on expanding plasma collection capabilities.

Kamada Ltd. (NASDAQ: KMDA) will announce its financial results for Q1 2021 on May 12, 2021, before the U.S. markets open. Management will hold a conference call at 8:30 AM ET the same day to discuss the results and address inquiries. Kamada's portfolio includes plasma-derived products such as GLASSIA and KEDRAB, with continued production agreements in place with Takeda Pharmaceuticals. The company is also advancing clinical trials for treatments related to COVID-19 and AAT deficiency. Kamada is focused on leveraging its manufacturing capabilities for profitable growth.

Kamada Ltd. (NASDAQ: KMDA) has announced a significant transition in its GLASSIA manufacturing process. Kamada will transfer the U.S. Biologics License Application (BLA) to Takeda by the end of 2021, receiving a $2 million payment for the transfer. Additionally, a final $5 million sales-based milestone payment from Takeda was accelerated. Despite this shift, Kamada will continue marketing GLASSIA outside Takeda's territories while investing in the development of an inhaled AAT product, currently in a Phase III clinical trial. Revenue forecasts include approximately $25 million from GLASSIA sales in 2021.

Kamada Ltd. (NASDAQ: KMDA) announced positive results from its Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived hyperimmune globulin treatment for COVID-19. Out of 12 patients, 11 recovered, with 7 discharged by Day 5. The treatment showed no infusion-related reactions, and IgG levels increased significantly, enhancing virus neutralization. The company continues supplying its IgG product to the Israeli Ministry of Health for COVID-19 patients, anticipating $3.4 million in revenue from the initial order to treat 500 patients. Manufacturing is ramping up for potential international demand.

Kamada Ltd. (NASDAQ: KMDA) announced that CEO Amir London will present a corporate overview at the Jefferies Virtual Global Plasma Summit on March 11, 2021, at 9:35 a.m. ET. The presentation will be accessible via a live webcast, with a replay available for 30 days post-event. Kamada specializes in plasma-derived biopharmaceuticals, featuring products like GLASSIA and KEDRAB. The company aims to drive growth from its product lines and ongoing clinical trials, including treatments for COVID-19 and AAT deficiency.

Kamada Ltd. (Nasdaq: KMDA) has completed the acquisition of an FDA-licensed plasma collection center from Blood and Plasma Research, Inc. for approximately $1.66 million. This strategic move aims to enhance Kamada's goal of becoming a fully integrated specialty plasma company. The company plans to expand the hyperimmune plasma collection capacity and leverage the newly acquired FDA license to open additional centers in the U.S. This acquisition marks a significant step towards growing Kamada’s hyperimmune IgG portfolio.

Kamada Ltd. (NASDAQ: KMDA) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the SEC. The report includes audited consolidated financial statements, accessible on the SEC's website and Kamada's investor relations site. Kamada specializes in plasma-derived biopharmaceuticals with a focus on orphan indications. Their leading product, GLASSIA®, is the first liquid AAT product approved by the FDA. Kamada also has a late-stage product pipeline, including inhaled AAT formulations and a new hyperimmune immunoglobulin for COVID-19 treatment.

Kamada Ltd. (NASDAQ: KMDA) reported full-year 2020 revenues of $133.2 million, aligning with guidance and marking a 5% increase from 2019. The company overcame operational challenges from the COVID-19 pandemic, achieving adjusted EBITDA of $25.1 million. Kamada has entered the U.S. plasma collection market through the acquisition of an FDA-approved facility, aiming to expand its hyperimmune IgG portfolio. Additionally, it is supplying a plasma-derived COVID-19 product to the Israeli Ministry of Health, expecting about $3.4 million in related revenue.

Kamada Ltd. (NASDAQ: KMDA), a plasma-derived biopharmaceutical company, will release its financial results for Q4 and fiscal year 2020 on February 10, 2021, before U.S. market open. A conference call will follow at 8:00 AM ET for discussion and Q&A. Kamada is known for its proprietary plasma-derived products, including GLASSIA® and KamRab®, both FDA-approved. The company has late-stage developments, including an inhaled AAT formulation and treatments for COVID-19. FIMI Opportunity Fund is the largest shareholder, owning about 21% of shares.